The global herpes labialis drugs market is anticipated to grow at a CAGR of 4.0% during the forecast period. Herpes labialis is a viral infection caused by the herpes simplex virus 1 (HSV-1). Herpes simplex virus type 1 (HSV-1) is a cause of recurrent vesiculoulcerative lesions of the oral or genital mucosa. It can also cause infection in the eye, skin, central nervous system, and/or visceral organs. Antiviral agents available for HSV infection include acyclovir, valacyclovir, and famciclovir. The growing prevalence of herpes labialis among children and adults across the globe is the factor that is driving the market growth. According to WHO, an estimated 3.7 billion people under age 50 (67%) have HSV-1 infection, and an estimated 491 million people aged 15–49 (13%) have HSV-2 infection globally. With increasing prevalence, it is expected that the demand for herpes labialis drugs will increase significantly.
Get Free Sample link @ https://www.omrglobal.com/request-sample/herpes-labialis-drugs-market
Besides, the rising government programs for sexually transmitted disease awareness are expected to propel market growth. As HSV-2 is mainly transmitted during sex through contact with genital or anal surfaces, skin, sores, or fluids of someone infected with the virus. However, the high cost of treatment and strict government rules and regulations related to drug approval is expected to impact the growth of the market.
Full report of Herpes Labialis Drugs Market available @ https://www.omrglobal.com/industry-reports/herpes-labialis-drugs-market
Segmental Outlook
The global herpes labialis drugs market is segmented based on type, route of administration, and distribution channel. Based on type, the market is sub-segmented into acyclovir, valacyclovir, penciclovir, famciclovir, and docosanol. Among these, the valacyclovir segment emerged as the fastest growing in the global herpes labialis drugs market. The drug is considered as finest for the treatment of herpes virus infections including herpes simplex viruses type 1 (HSV-1), type 2 (HSV-2), herpes labialis (cold sores), and herpes zoster(shingles), and herpes simplex(genital herpes). It helps in reducing the episode duration and time to healing. The increasing prevalence of herpes virus infections can lead to high demand for the drug, which in turn boosts market growth. As of 2016, 13.2% of the global population aged 15–49 was existing with HSV-2 infection and 66.6% with HSV-1. This high prevalence of the disease and the fact that resistance to current therapies is on the rise makes it imperative to develop and discover new methods of HSV prevention and management. Apart from these, acyclovir is likely to show the fastest growth during the forecast period. As acyclovir has the greatest in vitro activity against HSV-1 and HSV-2. However, famciclovir and valacyclovir have greater oral bioavailability than acyclovir and are dosed less frequently.
Based on the route of administration, the market is sub-categorized into oral, topical, and parenteral. Similarly, based on distribution channels, it is further divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/herpes-labialis-drugs-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
